Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
KRMD vs BDX vs BAX vs ICU
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Biotechnology
KRMD vs BDX vs BAX vs ICU — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Biotechnology |
| Market Cap | $207M | $55.53B | $9.04B | $29M |
| Revenue (TTM) | $43M | $21.36B | $11.32B | $881K |
| Net Income (TTM) | $-2M | $1.14B | $-1.10B | $-14M |
| Gross Margin | 60.1% | 46.5% | 30.1% | 95.3% |
| Operating Margin | -5.1% | 10.6% | -2.7% | -15.8% |
| Forward P/E | — | 12.3x | 9.2x | — |
| Total Debt | $3M | $19.18B | $10.00B | $574K |
| Cash & Equiv. | $9M | $851M | $1.97B | $2M |
KRMD vs BDX vs BAX vs ICU — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 22 | May 26 | Return |
|---|---|---|---|
| KORU Medical System… (KRMD) | 100 | 199.1 | +99.1% |
| Becton, Dickinson a… (BDX) | 100 | 111.3 | +11.3% |
| Baxter Internationa… (BAX) | 100 | 32.5 | -67.5% |
| SeaStar Medical Hol… (ICU) | 100 | 1.9 | -98.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KRMD vs BDX vs BAX vs ICU
Each card shows where this stock fits in a portfolio — not just who wins on paper.
KRMD is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 22.2%, EPS growth 56.1%, 3Y rev CAGR 13.8%
- 11.2% 10Y total return vs BDX's 80.2%
BDX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.66, yield 2.7%
- Lower volatility, beta 0.66, Low D/E 75.5%, current ratio 1.11x
- Beta 0.66, yield 2.7%, current ratio 1.11x
- 5.3% margin vs ICU's -15.5%
BAX is the clearest fit if your priority is value.
- Better valuation composite
ICU is the #2 pick in this set and the best alternative if growth and momentum is your priority.
- 12.0% revenue growth vs BAX's 5.7%
- +291.9% vs BAX's -41.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.0% revenue growth vs BAX's 5.7% | |
| Value | Better valuation composite | |
| Quality / Margins | 5.3% margin vs ICU's -15.5% | |
| Stability / Safety | Beta 0.66 vs BAX's 1.37, lower leverage | |
| Dividends | 2.7% yield, 1-year raise streak, vs BAX's 3.9%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +291.9% vs BAX's -41.8% | |
| Efficiency (ROA) | 2.1% ROA vs ICU's -88.0% |
KRMD vs BDX vs BAX vs ICU — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
KRMD vs BDX vs BAX vs ICU — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BAX leads in 1 of 6 categories
BDX leads 1 • KRMD leads 1 • ICU leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — BDX and ICU each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BDX is the larger business by revenue, generating $21.4B annually — 24250.9x ICU's $881,000. BDX is the more profitable business, keeping 5.3% of every revenue dollar as net income compared to ICU's -15.5%. On growth, ICU holds the edge at +169.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $43M | $21.4B | $11.3B | $881,000 |
| EBITDAEarnings before interest/tax | -$1M | $4.2B | $671M | -$14M |
| Net IncomeAfter-tax profit | -$2M | $1.1B | -$1.1B | -$14M |
| Free Cash FlowCash after capex | $179,290 | $3.1B | $501M | -$14M |
| Gross MarginGross profit ÷ Revenue | +60.1% | +46.5% | +30.1% | +95.3% |
| Operating MarginEBIT ÷ Revenue | -5.1% | +10.6% | -2.7% | -15.8% |
| Net MarginNet income ÷ Revenue | -5.3% | +5.3% | -9.7% | -15.5% |
| FCF MarginFCF ÷ Revenue | +0.4% | +14.7% | +4.4% | -16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.1% | -10.6% | +2.9% | +169.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +33.3% | -2.0% | -112.0% | +88.2% |
Valuation Metrics
BAX leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, BDX's 14.7x EV/EBITDA is more attractive than BAX's 25.4x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $207M | $55.5B | $9.0B | $29M |
| Enterprise ValueMkt cap + debt − cash | $201M | $73.9B | $17.1B | $28M |
| Trailing P/EPrice ÷ TTM EPS | -77.76x | 26.29x | -10.01x | -0.73x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 12.27x | 9.17x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 1.59x | — | — |
| EV / EBITDAEnterprise value multiple | — | 14.65x | 25.37x | — |
| Price / SalesMarket cap ÷ Revenue | 5.02x | 2.54x | 0.80x | 215.18x |
| Price / BookPrice ÷ Book value/share | 12.03x | 1.73x | 1.47x | — |
| Price / FCFMarket cap ÷ FCF | — | 20.80x | 27.99x | — |
Profitability & Efficiency
BDX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
BDX delivers a 4.5% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-119 for ICU. KRMD carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to BAX's 1.64x. On the Piotroski fundamental quality scale (0–9), BDX scores 7/9 vs BAX's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -13.6% | +4.5% | -16.5% | -119.2% |
| ROA (TTM)Return on assets | -8.3% | +2.1% | -5.4% | -88.0% |
| ROICReturn on invested capital | -19.5% | +4.3% | -1.4% | — |
| ROCEReturn on capital employed | -14.9% | +5.4% | -1.7% | — |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.21x | 0.76x | 1.64x | — |
| Net DebtTotal debt minus cash | -$5M | $18.3B | $8.0B | -$1M |
| Cash & Equiv.Liquid assets | $9M | $851M | $2.0B | $2M |
| Total DebtShort + long-term debt | $3M | $19.2B | $10.0B | $574,000 |
| Interest CoverageEBIT ÷ Interest expense | — | 4.09x | -0.83x | -209.88x |
Total Returns (Dividends Reinvested)
KRMD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KRMD five years ago would be worth $12,402 today (with dividends reinvested), compared to $189 for ICU. Over the past 12 months, ICU leads with a +291.9% total return vs BAX's -41.8%. The 3-year compound annual growth rate (CAGR) favors KRMD at 4.2% vs ICU's -53.7% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -20.9% | +0.7% | -10.2% | +84.7% |
| 1-Year ReturnPast 12 months | +63.2% | +51.8% | -41.8% | +291.9% |
| 3-Year ReturnCumulative with dividends | +13.3% | +5.0% | -56.3% | -90.1% |
| 5-Year ReturnCumulative with dividends | +24.0% | +16.9% | -74.3% | -98.1% |
| 10-Year ReturnCumulative with dividends | +1116.4% | +80.2% | -42.4% | -98.1% |
| CAGR (3Y)Annualised 3-year return | +4.2% | +1.6% | -24.1% | -53.7% |
Risk & Volatility
Evenly matched — BDX and ICU each lead in 1 of 2 comparable metrics.
Risk & Volatility
BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than BAX's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICU currently trades 95.6% from its 52-week high vs BAX's 53.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.15x | 0.66x | 1.37x | 1.06x |
| 52-Week HighHighest price in past year | $6.61 | $205.52 | $32.68 | $5.08 |
| 52-Week LowLowest price in past year | $2.63 | $100.31 | $15.73 | $0.22 |
| % of 52W HighCurrent price vs 52-week peak | +67.2% | +74.6% | +53.6% | +95.6% |
| RSI (14)Momentum oscillator 0–100 | 42.9 | 32.2 | 44.0 | 65.7 |
| Avg Volume (50D)Average daily shares traded | 138K | 2.5M | 8.7M | 150K |
Analyst Outlook
Evenly matched — BDX and BAX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: KRMD as "Buy", BDX as "Buy", BAX as "Hold". Consensus price targets imply 57.7% upside for KRMD (target: $7) vs 12.8% for BDX (target: $173). For income investors, BAX offers the higher dividend yield at 3.87% vs BDX's 2.72%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | — |
| Price TargetConsensus 12-month target | $7.00 | $172.85 | $19.75 | — |
| # AnalystsCovering analysts | 5 | 33 | 36 | — |
| Dividend YieldAnnual dividend ÷ price | — | +2.7% | +3.9% | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | 0 | — |
| Dividend / ShareAnnual DPS | — | $4.17 | $0.68 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.8% | 0.0% | 0.0% |
BAX leads in 1 of 6 categories (Valuation Metrics). BDX leads in 1 (Profitability & Efficiency). 3 tied.
KRMD vs BDX vs BAX vs ICU: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is KRMD or BDX or BAX or ICU a better buy right now?
For growth investors, KORU Medical Systems, Inc.
(KRMD) is the stronger pick with 22. 2% revenue growth year-over-year, versus 5. 7% for Baxter International Inc. (BAX). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate KORU Medical Systems, Inc. (KRMD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — KRMD or BDX or BAX or ICU?
On forward P/E, Baxter International Inc.
is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — KRMD or BDX or BAX or ICU?
Over the past 5 years, KORU Medical Systems, Inc.
(KRMD) delivered a total return of +24. 0%, compared to -98. 1% for SeaStar Medical Holding Corporation (ICU). Over 10 years, the gap is even starker: KRMD returned +1116% versus ICU's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — KRMD or BDX or BAX or ICU?
By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.
66β versus Baxter International Inc. 's 1. 37β — meaning BAX is approximately 108% more volatile than BDX relative to the S&P 500. On balance sheet safety, KORU Medical Systems, Inc. (KRMD) carries a lower debt/equity ratio of 21% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — KRMD or BDX or BAX or ICU?
By revenue growth (latest reported year), KORU Medical Systems, Inc.
(KRMD) is pulling ahead at 22. 2% versus 5. 7% for Baxter International Inc. (BAX). On earnings-per-share growth, the picture is similar: SeaStar Medical Holding Corporation grew EPS 78. 1% year-over-year, compared to -37. 8% for Baxter International Inc.. Over a 3-year CAGR, KRMD leads at 13. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — KRMD or BDX or BAX or ICU?
Becton, Dickinson and Company (BDX) is the more profitable company, earning 7.
7% net margin versus -183. 9% for SeaStar Medical Holding Corporation — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus -132. 2% for ICU. At the gross margin level — before operating expenses — ICU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is KRMD or BDX or BAX or ICU more undervalued right now?
On forward earnings alone, Baxter International Inc.
(BAX) trades at 9. 2x forward P/E versus 12. 3x for Becton, Dickinson and Company — 3. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KRMD: 57. 7% to $7. 00.
08Which pays a better dividend — KRMD or BDX or BAX or ICU?
In this comparison, BAX (3.
9% yield), BDX (2. 7% yield) pay a dividend. KRMD, ICU do not pay a meaningful dividend and should not be held primarily for income.
09Is KRMD or BDX or BAX or ICU better for a retirement portfolio?
For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
66), 2. 7% yield). Both have compounded well over 10 years (BDX: +80. 2%, ICU: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between KRMD and BDX and BAX and ICU?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KRMD is a small-cap high-growth stock; BDX is a mid-cap quality compounder stock; BAX is a small-cap income-oriented stock; ICU is a small-cap quality compounder stock. BDX, BAX pay a dividend while KRMD, ICU do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.